Leukemia stem cell test to predict relapse in acute myeloid leukemia
Studies a flow cytometry test for leukemia stem cells in people with acute myeloid leukemia.
Plain-language title generated from the registry record
Registry title: Leukemia Stem Cell-based Assay to Predict Relapse and Survival in Patients With Acute Myeloid Leukemia
Key facts
- Where
- Beijing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 6 to 60 with acute myeloid leukemia who have an MLL rearrangement and are getting chemotherapy or a donor stem cell transplant.
- Age
- 6 to 60 years
- Sex
- All sexes can join.
- Disease stage
- Acute myeloid leukemia with an MLL rearrangement.
- Earlier treatment
- People are receiving chemotherapy or an allogeneic (donor) hematopoietic stem cell transplant.
- Biomarker or test result
- MLL rearrangement.
Main reasons for not taking part
- People who cannot receive chemotherapy or an allogeneic hematopoietic stem cell transplant
- People who cannot comply with the study
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 6 and 60 years old?
Source: NCT07537738, who can take part
Where in China
- Peking University People's HospitalBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Peking University People's Hospital
- Trial code
- NCT07537738
- Record updated
- 17 April 2026
- Original description
The goal of this observational study is to learn about the predict value of leukemia stem cell for acute myeloid leukemia patients with MLL-rearrangement. The main question it aims to answer is:Read full original descriptionShow less
Leukemia Stem Cell-based Assay to Predict Relapse and Survival in Patients With Acute Myeloid Leukemia
The goal of this observational study is to learn about the predict value of leukemia stem cell for acute myeloid leukemia patients with MLL-rearrangement. The main question it aims to answer is:
• Could be leukemia stem cell used for relapse prediction in acute myeloid leukemia patients with MLL-rearrangement? Leukemia stem cell will be detected at the same time for participants who detected minimal residual disease using bone marrow as part of their regular medical care to answer the question.
Inclusion: Acute myeloiud leukemia patients with MLL arrangement aging 6-60 years recieving chemoterapy or allo-geneic hematopoietic stem cell transplantation.
Exclusion: Patients who cannot recieve chemoterapy or allo-geneic hematopoietic stem cell transplantation; Patients who cannot comply with the study.